Article Details

JetBlue, but for biopharma: Alexis Borisy's EQRx nabs $200M, takes aim at drug prices

Retrieved on: 2020-01-12 01:48:45

Tags for this article:

Click the tags to see associated articles and topics

JetBlue, but for biopharma: Alexis Borisy's EQRx nabs $200M, takes aim at drug prices. View article details on hiswai:

Excerpt

<div>(<b>Third Rock Ventures</b>) ... recently chief business officer at Foundation Medicine, the first biotech Borisy founded as a partner at <b>Third Rock Ventures</b>.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up